ivabradine / Generic mfg. - LARVOL DELTA

Ivabradine in acute care: Revisiting the funny current in critical care context. (PubMed, World J Crit Care Med) - "This review examines its mechanism of action, clinical applications, comparative efficacy, and safety profile. It incorporates recent literature to assess its expanding role in managing acute coronary syndrome, acute decompensated heart failure, and sepsis-induced tachycardia."

Journal • Review • Acute Coronary Syndrome • Cardiovascular • Congestive Heart Failure • Critical care • Heart Failure • Infectious Disease • Septic Shock

Ivabradine Use for Arrhythmias in Children. (PubMed, Ann Pharmacother) - "Ivabradine was safe and effective as additive therapy for the treatment of pediatric arrhythmias. Larger studies of ivabradine use in pediatric arrhythmias are needed."

Journal • Atrial Fibrillation • Cardiovascular • Pediatrics

Ivabradine in the treatment of congenital junctional ectopic tachycardia: a case report and review of the literature. (PubMed, Cardiol Young) - "This report presents a case of neonatal-onset congenital junctional ectopic tachycardia treated with cedilanid, amiodarone, and propafenone but persisted in episodes. The review of the literature indicates that ivabradine demonstrates efficacy in the treatment of paediatric junctional ectopic tachycardia, particularly in refractory cases, without significant side effects. These findings suggest that ivabradine has broad applications in the treatment of refractory arrhythmias."

Journal • Cardiovascular • Pediatrics

Ivabradine as a treatment for postural orthostatic tachycardia syndrome: A systematic review. (PubMed, J Cardiovasc Pharmacol) - "In conclusion, there is low-quality evidence derived from small observational studies and one small randomized trial that ivabradine is effective in reducing heart rate and improving symptoms in patients with POTS. The exact role of ivabradine in treatment of POTS needs to be clarified in further randomized trials and more robust evidence."

Journal • Cardiovascular • Fatigue • Pain

Successful Treatment With Ivabradine for Junctional Ectopic Tachycardia-Induced Cardiomyopathy With Hypoplastic Left Heart Syndrome. (PubMed, J Arrhythm) - "A patient with hypoplastic left heart syndrome developed heart failure due to tachycardia-induced cardiomyopathy from junctional ectopic tachycardia. Conventional antiarrhythmic therapy was ineffective, but ivabradine successfully controlled the arrhythmia and improved both ventricular function and heart failure."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Ventricular Tachycardia

HEART-BEAT: Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease (clinicaltrials.gov) - P2/3 | N=350 | Not yet recruiting | Sponsor: Gødstrup Hospital

New P2/3 trial • Cardiovascular • Coronary Artery Disease • Heart Failure

Ivabradine, atrial fibrillation and stroke: a combined meta-analysis and FAERS disproportionality analysis. (PubMed, Front Pharmacol) - "Our findings raise the hypothesis that ivabradine facilitates an increased diagnosis rather than playing a direct role in causing AF. Prospective studies with continuous ECG monitoring and standardized endpoints are needed to clarify the temporal and mechanistic relationship between ivabradine, AF recognition, and cerebrovascular risk."

Journal • Retrospective data • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Carbonylative Ring Expansion of Cyclic Carboxylic Acids. (PubMed, J Am Chem Soc) - "In such cases, mechanistic studies indicated that the reaction would proceed via ring opening through C-C bond homolysis on the ketyl radical, followed by a reductive radical-polar crossover of the resultant benzyl radical to the benzyl anion, which then participates in the recyclization. When coupled with α-amino C-H carboxylation of cyclic aliphatic amines, this process functions as a molecular editing platform that enables the carbonylative ring expansion of ticlopidine and nicotine as well as the streamlined synthesis of an ivabradine fragment."

Journal

Effect of Sacubitril/Valsartan, Ivabradine, and Captopril on Anxiety-like Behavior in Spontaneously Hypertensive Rats. (PubMed, Int J Mol Sci) - "Additionally, correlation analysis indicated that anxiety-like behavior in Wistar rats or SHR, either with or without cardiovascular therapy, was independent of SBP, HR, LVW, or LVHP. The level of anxiety-like behavior can, therefore, be considered part of the inherent neurobehavioral traits unrelated to fundamental hemodynamic or structural cardiovascular parameters."

Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Mood Disorders • Psychiatry

Engineering Imine Reductase for the Synthesis of Pharmaceutically Relevant 1-Aminomethylbenzocycloalkanes via Dynamic Kinetic Resolution-Asymmetric Reductive Amination. (PubMed, Org Lett) - "Here, an imine reductase variant (IR215-L97F/L187Q/A239M) was identified, showing a 277-fold increase in the catalytic efficiency and enhanced stereoselectivity (>99% ee) for the synthesis of (1S)-4,5-dimethoxy-1-[(methylamino)methyl]benzocyclobutane (a key intermediate of ivabradine). This variant enabled the synthesis of a range of different substituted chiral 1-aminomethylbenzocyclobutanes and one example of a 1-aminomethylbenzocyclohexane with up to >99% ee values and 89% isolated yield, providing an efficient protocol for accessing pharmaceutically valuable compounds."

Journal

Distal HCN channels mediate, while potassium channels modulate, ectopic action potential generation in neocortical parvalbumin positive interneurons. (AES 2025) - "Tetraethylammonium (TEA) abolished ectopic action potentials in 6/13 PV+ cells, and 4-aminopyridine (4AP) decreased ectopic action potential initiation threshold and increased robustness in all 13 neurons, suggesting a heterogeneous contribution of voltage-gated potassium subtypes to ectopic action potential generation. The hyperpolarization activated cation channel (HCNC) antagonist Ivabradine (30 μM) abolished ectopic action potential generation in 7/10 cells and diminished robustness in all 10 cells. Given prior associations between HCNC deficiencies and some epilepsies, as well as potassium channel abnormalities and epilepsies, our data suggest that ectopic action potential generation in PV+ cells should be investigated as a potential contributor to seizure genesis and propagation."

Late-breaking abstract • CNS Disorders • Epilepsy

Inhibition of HCN Channels Promotes Antiseizure Effects in a Genetic Model of Mixed Generalized Epilepsies (AES 2025) - "Here, we investigate the effects of Ivabradine hydrochloride (IVA), a HCN channel blocker and FDA-approved drug for heart failure, on acoustically evoked seizure susceptibility in genetically epilepsy-prone rats (GEPR-3s). For the acute treatment experiment, male (n=10) and female (n=10) GEPR-3s were used; each GEPR-3 was used as its respective control (vehicle-treated)... Furthermore, the findings suggest that HCN channels play a role in the mechanisms underlying seizure termination while also impacting the seizure threshold. These findings highlight the potential of blocking HCN channels as a promising strategy in the management of inherited epilepsy, particularly in epilepsy patients who are also diagnosed with heart failure or arrhythmias."

Cardiovascular • CNS Disorders • Congestive Heart Failure • Epilepsy • Heart Failure

Ivabradine for prevention of myocardial injury after noncardiac surgery (PREVENT-MINS trial): study protocol for a randomized controlled trial. (PubMed, Trials) - P3 | "ClinicalTrials.gov NCT05279651. Registered on 4 March 2022."

Clinical protocol • Journal • Atherosclerosis • Cardiovascular • Hypotension

Critical Evaluation of Ivabradine's Cardioprotective Potential Against Anthracycline-Induced Cardiotoxicity: A Comprehensive Review of Clinical Trials, Preclinical Studies, and Current Treatment Guidelines. (PubMed, Cardiovasc Drugs Ther) - No abstract available

Journal • Preclinical • Cardiovascular

Immune regulation following allogeneic iPSC-derived cardiomyocyte transplantation in non-human primates. (PubMed, Cardiovasc Res) - "These findings highlight the importance of optimised immunosuppressant regimens for iPSC-CM graft survival and the potential improvements in clinical outcomes in patients with severe heart failure."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Transplant Rejection • Transplantation

Relationship between heart function, fibrosis and AT1 receptors in the heart and the kidneys of a mouse model of doxorubicin-induced cardiomyopathy (AHA 2025) - "Introduction: Ivabradine (IVAB) is an effective heart-rate lowering drug used in patients with heart failure. Improved cardiac function by IVAB is not due to reduced fibrosis, despite sustained normal renal AT1R expression. This may explain the rapid relapse in cardiac dysfunction once the drug is stopped."

Preclinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology

Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS). (PubMed, Clin Auton Res) - "For pharmaceuticals, several studies showed significant effects following therapy with ivabradine and β-adrenergic blocking agents. There are single studies which imply that midodrine (hydrochloride) and pyridostigmine seem to have a beneficial effect on hemodynamics in POTS."

Journal • Review • Cardiovascular • CNS Disorders • Fatigue • Hypotension • Infectious Disease

Heart rate management using ivabradine in acute myocardial infarction: a propensity score-matched single-center study. (PubMed, Sci Rep) - "Subgroup analysis demonstrated a decreased rehospitalization risk following ivabradine therapy in females (HR: 0.44; 95% CI: 0.22-0.89, P = 0.023), and patients with heart rate > 70 bpm (HR: 0.59; 95% CI: 0.40-0.89, P = 0.011), Killip classification > 1 (HR: 0.62; 95% CI: 0.39-0.99, P = 0.046), anterior wall myocardial infarction (HR: 0.49; 95% CI: 0.26-0.93, P = 0.029), > 1 diseased vessel (HR: 0.59; 95% CI: 0.38-0.93, P = 0.023), and no chronic kidney disease (CKD) (HR: 0.67; 95% CI: 0.46-0.98, P = 0.040) or clopidogrel therapy (HR: 0.54; 95% CI: 0.32-0.90, P = 0.019). In conclusion, ivabradine therapy during hospitalization was associated with a lower risk of all-cause rehospitalization in patients with AMI. However, the robustness of our findings requires further validation."

Journal • Cardiovascular • Chronic Kidney Disease • Myocardial Infarction • Nephrology • Renal Disease

Ivabradine, a hyperpolarization-activated channel blocker, attenuates mechanical, but not heat, hypersensitivity in hyperglycemic and normoglycemic rat models of diabetic neuropathy. (PubMed, J Drug Target) - "We found that: (a) diabetic (hyperglycemic) and non-diabetic (normoglycemic) STZ rats, as well as normoglycemic HFD/ZTZ rats, exhibit mechanical and heat hypersensitivity, evidenced by reduced paw withdrawal thresholds and latencies, respectively, and (b) ivabradine (10 mg/kg, i.p.), the clinically approved HCN blocker, was as effective as the positive control gabapentin in attenuating mechanical, but not heat, hypersensitivity, in both models. These findings reinforce that factors beyond hyperglycemia contribute to DPNP and highlight HCN channels as potential therapeutic targets for treating DPNP."

Journal • Preclinical • Diabetes • Diabetic Neuropathy • Immunology • Metabolic Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Cost-Effectiveness Model of Ranolazine for Treating Chronic Stable Angina Patients From Kingdom of Saudi Arabia Perspective (ISPOR-EU 2025) - "This insight, along with the importance of stratifying outcomes by angina severity and including revascularization impacts, guided the development of a 1-year decision tree model which compared ranolazine+sublingual nitro-glycerine (SNG) against placebo+SNG and trimetazidine+SNG. Trimetazidine was selected as the comparator due to its lower cost, high prevalence (approximately 95%) in Saudi Arabian second-line treatments, and superior safety profile compared to Ivabradine... Ranolazine is a cost-effective treatment compared to placebo and trimetazidine from KSA payor perspective. These findings are vital for optimizing healthcare resource allocation and ensuring patient access amidst rising costs."

Clinical • Cost effectiveness • HEOR • Cardiovascular

Prescription Drug Coverage of Guideline-Directed Medical Therapy for People Living with Heart Failure with Reduced Ejection Fraction in Canada. (PubMed, CJC Open) - "In all provincial and territorial plans, patient eligibility and prior medication use criteria are required for sacubitril-valsartan reimbursement...Carvedilol coverage is not a benefit in Ontario or British Columbia. Bisoprolol and spironolactone have universal coverage. Eplerenone is not listed in British Columbia. Dapagliflozin coverage is a benefit in all plans except Quebec. Ivabradine coverage has patient eligibility and prior medication use criteria in all provinces and territories and prescriber restrictions in certain regions...Coverage criteria include prior medication use and prescriber qualifications, which are not supported by evidence-based guidelines. Systemwide changes in the funding of drug reimbursement programs are needed to improve access to GDMT for the more than 750,000 people living with HF in Canada."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Role of Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels in a hPSC Model of First Heart Field-Derived Ventricular Development (AHA 2025) - "Ivabradine, a more specific but use-dependent HCN blocker, had no effect, likely due to limited channel activity in FHF progenitors, which do not exhibit rhythmic firing... HCN4 is actively transcribed in a hPSC model of FHF development. Its knockdown did not affect expression of most FHF and vCM markers. Pharmacological inhibition of HCN channels significantly reduced ATP levels in the progenitors with greater sensitivity in FHF, a development timepoint known to exhibit a shift toward oxidative metabolism."

Amyloidosis • Cardiovascular

Tachycardia-induced Cardiomyopathy from Incessant Atrial Tachycardia in a Teenager with Severe Pectus Excavatum (AHA 2025) - "Initial medical therapy with ivabradine, flecainide, and atenolol led to rate control and subsequent improvement in left ventricular function but failed to terminate the arrhythmia...Postoperatively, left ventricular function normalized, but AT persisted despite continued escalation to ivabradine, sotalol, and flecainide...The p wave morphology on electrocardiogram, left atrial deformity on echocardiogram, and intracardiac activation map of the AT focus in this case, support cardiac compression as the mechanism for AT. These findings suggest the potential for sustained atrial remodeling with subsequent arrhythmia in the context of PE and underscores the importance of cardiac screening in asymptomatic adolescents with severe chest wall deformities."

Cardiomyopathy • Cardiovascular • Pediatrics

LAUGHING ALL THE WAY TO RECOVERY: FUNNY CHANNELS REVERSE CARDIOMYOPATHY IN SINUS TACHYCARDIA (CHEST 2025) - "The patient was initially started on metoprolol succinate 50mg daily and Entresto 24/26 twice a day and a wearable cardioverter-defibrillator was implemented. The patient trialed on increased metoprolol succinate 75mg daily with addition of Jardiance 10mg daily, but unfortunately did not tolerate due to hypotension... Chronic, asymptomatic sinus tachycardia has the potential to cause severe TIC. Ivabradine, with its unique funny channel blockade, offers a promising treatment, especially for patients intolerant to up-titration of beta blockade."

Cardiomyopathy • Cardiovascular • Hypotension

Ivabradine and Atrial Fibrillation Incidence: A Nested Matching Study. (PubMed, JACC Adv) - "The risk of AF over 180-day period was higher among HF patients who received IVB vs those who did not receive IVB. Further studies are warranted to understand this association, including the impact of unmeasured risk factors and confounding by indication."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure